

## Dr Anthony Hubbard

### Publications

Sprandel U, **Hubbard AR**, Chalmers RA (1979) In vitro studies on resealed erythrocyte 'ghosts' as protein carriers. *Res Exp Med* 175, 239-245

Sprandel U, **Hubbard AR**, Chalmers RA (1979) Membrane transport in resealed haemoglobin-containing human erythrocyte 'ghosts' prepared by a dialysis procedure. *Biochem Bioph Res Co* 91, 79-85

**Hubbard AR**, Sprandel U, Chalmers RA (1980) Organic acid transport in resealed haemoglobin-containing human erythrocyte 'ghosts'. *Biochem J* 190, 653-658

Sprandel U, Clark JB, **Hubbard AR**, Chalmers RA (1981) Morphology of haemoglobin-containing human erythrocyte 'ghosts'. *Micron* 12, 29-36

Sprandel U, **Hubbard AR**, Chalmers RA (1981) In vivo-Überlebeszeit von erythrozytenschatten als Trägersysteme für Pharmaka. *Verh Dt Ges Inn Med* 87: 1172-1174

Sprandel U, **Hubbard AR**, Chalmers RA (1981) Towards enzyme therapy using carrier erythrocytes. *J Inher Metab Dis* 4, 99-100

**Hubbard AR** and Chalmers RA (1982) Entrapment of enzymes into human erythrocyte 'ghosts'. In: *Advances in the treatment of inborn errors of metabolism*. (Crawford M d'A, Gibbs DA and Watts RWE eds) John Wiley and Sons, Chichester, p330

**Hubbard AR**, Miller JN, Law B, Mason P, Moffat A C (1983) A polarisation fluoroimmunoassay for LSD. *Anal Proc* 20, 606-608

**Hubbard AR**, Jennings CA, Barrowcliffe TW (1984) Anticoagulant properties in vitro of heparan sulphates. *Thromb Res* 35, 567-576

**Hubbard AR**, Jennings CA (1985) Neutralisation of heparan sulphate and low molecular weight heparin by protamine. *Thromb Haemostasis* 53, 86-89

Barrowcliffe TW, Curtis AD, Tomlinson TP, **Hubbard AR**, Johnson EA, Thomas DP (1985) Standardisation of low molecular weight heparins: a collaborative study. *Thromb Haemostasis* 54, 675-679

**Hubbard AR**, Jennings CA (1986) Inhibition of tissue thromboplastin-mediated blood coagulation. *Thromb Res* 42, 489-498

Barrowcliffe TW, Gray E, Merton RE, Dawes J, Jennings CA, **Hubbard AR**, Thomas DP (1986) Anticoagulant activities of pentosan polysulphate (Hemoclar) due to release of hepatic triglyceride lipase (HTGL). *Thromb Haemostasis* 56, 202-206

**Hubbard AR**, Curtis AD, Barrowcliffe TW, Edwards SJ, Jennings CA, Kemball-Cook G (1986) Assay of Factor VIII concentrates: comparison of the chromogenic and two-stage clotting assays. *Thromb Res* 44, 887-891

**Hubbard AR**, Jennings CA (1987) Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. *Thromb Res* 46, 527-537

Poole S, Thorpe R, Meager A, **Hubbard AR**, Gearing AJH (1988) Detection of pyrogen by cytokine release. *Lancet* 1, 130

**Hubbard AR** (1988) Standardisation of Protein C in plasma: establishment of an international standard. *Thromb Haemostasis* 59, 464-467

**Hubbard AR**, Parr LJ (1989) The effect of phospholipase C on plasma factor VII. *Brit J Haematol* 73, 360-364

Barrowcliffe TW, Marshall DF, Trickett LP, **Hubbard AR**, Gray E, Thorpe R (1989) Procoagulant activity of T lymphoblastoid cells in extrinsic and intrinsic coagulation systems. *Thromb Haemostasis* 62, 880-884

**Hubbard AR**, Parr LJ (1991) Phospholipase C mediated inhibition of factor VII requires triglyceride-rich lipoproteins. *Thromb Res* 62, 335-344

**Hubbard AR**, Parr LJ, Baines MG (1992) Pregnancy and Factor VII. *Brit J Haematol* 80, 265-266

Quinlan G J, Coudray C, **Hubbard AR**, Gutteridge JMC (1992) Vanadium and copper in clinical solutions of albumin and their potential to damage protein structure. *J Pharm Sci* 81, 611-614

**Hubbard AR**, Wong MY (1992) A collaborative study on the measurement of Protein S antigen in plasma. *Thromb Haemostasis* 68, 115-118

**Hubbard AR**, Weller LJ, Gray E (1994) Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. *Blood Coagul Fibrin* 5, 819-823

**Hubbard AR**, Barrowcliffe TW (1994) Measurement of activated factor VII using soluble mutant tissue factor - proposal for standardization. *Thromb Haemostasis* 72, 649-650

Lee C, Barrowcliffe T, Bray G, Gomperts E, **Hubbard A**, Kemball-Cook G, Lilley P, Owens D, Von Tilberg L, Pasi J (1996) Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil -M. *Thromb Haemostasis* 76, 950-956

**Hubbard AR**, Margetts SML, Barrowcliffe TW (1997) International Normalized Ratio determination using calibrated reference plasmas. *Brit J Haematol* 98, 74-78

**Hubbard AR** (1997) Standardisation of Protein S in plasma: Calibration of the 1st International Standard. *Thromb Haemostasis* 78, 1237-1241

Raut S, Di Giambattista M, Bevan S, **Hubbard AR**, Barrowcliffe TW, Laub R (1998) Modification of

factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. *Thromb Haemostasis* 80, 624-631

Barrowcliffe TW, Raut S, **Hubbard AR** (1998) Discrepancies in potency assessment of recombinant FVIII concentrates. *Haemophilia* 4, 634 - 640

**Hubbard AR**, Margetts SML, Weller LJ, Macnab J, Barrowcliffe TW (1999) An international collaborative study on the INR calibration of freeze-dried reference plasmas. *Brit J Haematol* 104, 455-460

Whitton CM, Sands D, **Hubbard AR**, Gaffney PJ (2000) A collaborative study to establish the 2nd International Standard for Fibrinogen plasma. *Thromb Haemostasis* 84, 258-262

Souter PJ, Thomas S, **Hubbard AR**, Poole S, Römisch J, Gray E (2001) Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. *Crit Care Med* 29, 134-139

**Hubbard AR**, Rigsby P, Barrowcliffe TW (2001) Standardisation of Factor VIII and von Willebrand Factor in plasma: calibration of the 4th International Standard. *Thromb Haemostasis* 85, 634-638

**Hubbard AR**, Bevan SA, Weller LJ (2001) Potency estimation of recombinant factor VIII: effect of assay method and standard. *Brit J Haematol* 113, 533-536

**Hubbard AR**, Weller LJ, Bevan SA (2002) A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. *Brit J Haematol* 117, 247-248

**Hubbard AR**, Weller LJ, Bevan SA (2002) Activation profiles of FVIII in concentrates reflect one-stage/chromogenic potency discrepancies. *Brit J Haematol* 117, 957-960

**Hubbard AR**, Sands D, Chang AC, Mazurier C (2002) Standardisation of von Willebrand Factor in therapeutic concentrates: calibration of the 1st International Standard for von Willebrand Factor Concentrate (00/514). *Thromb Haemostasis* 88, 380-386

Barrowcliffe TW, Raut S, Sands D, **Hubbard AR** (2002) Coagulation and chromogenic assays of Factor VIII activity: general aspects, standardization and recommendations. *Semin Thromb Hemost* 28, 247-255

**Hubbard AR**, Sands D, Sandberg E, Seitz R, Barrowcliffe TW (2003) A multi-centre collaborative study on the potency estimation of ReFacto. *Thromb Haemostasis* 90, 1088 - 93

**Hubbard AR**, Heath AB (2004) Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). *J Thromb Haemost* 2, 1380-4

Raut S, Bevan S, **Hubbard AR**, Sands D, Barrowcliffe TW (2004) A collaborative study to establish the 7th International Standard for Factor VIII Concentrate. *J Thromb Haemost* 3, 119-126

Favaloro EJ, Lillicrap D, Lazzari MA, Cattaeno M, Mazurier C, Woods A, Meschengieser S, Blanco A, Kempfer AC, **Hubbard A**, Chang A (2004) von Willebrand Disorder: Laboratory aspects to diagnosis and treatment. *Hemophilia* 10, (Suppl 4), 164-8

**Hubbard AR** (2006) von Willebrand Factor Standards for plasma and concentrate testing. *Semin Thromb Hemost* 32, 522-528

**Hubbard AR**, Bevan S, Matejtschuk P (2007) Impact of residual moisture and formulation on Factor VIII and Factor V recovery in lyophilized plasma reference materials. *Anal Bioanal Chem* 387, 2503-7

**Hubbard AR** (2007) International Biological Standards for coagulation factors and inhibitors. *Semin Thromb Hemost* 33, 283-289

**Hubbard AR**, Weller, LJ, Johnes S (2007) Calibration of the WHO 1st International Standard for blood coagulation Factor V in plasma, human (03/116). *J Thromb Haemost* 5, 1318-9

Fryer JF, **Hubbard AR**, Baylis SA (2007) Human parvovirus PARV4 in clotting factor VIII concentrates. *Vox Sang* 93, 341-347

**van den Besselaar AMHP**, Hubbard AR, Tripodi A (2008) **Continuation of the International Standard thromboplastin (human, recombinant, plain) by means of a replacement reconstitution fluid.** *J Thromb Haemost* 6, 1042-3

Raut S and **Hubbard A R** (2010) International Reference Standards in Coagulation. *Biologicals* 38, 423-9

Tripodi A, Chantarangkul V, van den Besselaar AMHP, Witteveen E, **Hubbard AR**, Baglin T (2010) International Collaborative Study for the Calibration of a Proposed International Standard for Thromboplastin, Human, Plain. *J Thromb Haemost.* 8, 2066-8

Lee CA, **Hubbard A**, Sabin CA, Budde U, Castaman G, Favaloro EJ, Friedman KD, Federici AB (2011) Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilised plasmas. *J Thromb Haemost.* 9, 220-2

**Hubbard AR**, Kitchen S, Beeharry M, Bevan SA, Bowyer A (2011) Long-term stability of the Scientific and Standardization Committee Secondary Coagulation Standard (SSC Lot no. 3). *J Thromb Haemost.* 9, 1246-8

**Hubbard AR**, Hamill M, Beeharry M, Bevan SA, Heath AB (2011) Value assignment of the WHO 2nd International Standard von Willebrand factor, concentrate (09/182). *J Thromb Haemost* 9, 1638-40

**Hubbard AR**, Hamill M, Beeharry M, Bevan SA, Heath AB (2011) Value assignment of the WHO 6<sup>th</sup> International Standard for Blood Coagulation Factor VIII and von Willebrand factor in Plasma (07/316). *J Thromb Haemost* 9, 2100-2

**Hubbard AR**, Hamill M, Eikenboom HCJ, Montgomery RR, Mertens K, Haberichter S (2012) Standardisation of von Willebrand factor propeptide: value assignment to the WHO 6<sup>th</sup> IS Factor VIII/von Willebrand factor, plasma (07/316). *J Thromb Haemost* 10, 959-60

Barrowcliffe TW, **Hubbard AR**, Kitchen S (2012) Standards and monitoring treatment. *Haemophilia* 18 (suppl. 4) 61-65

Barrowcliffe TW, **Hubbard AR** (2013) International standards in hemostasis. in *Quality in Laboratory*

Hemostasis and Thrombosis. Second Edition. S Kitchen, J D Olson, F E Preston eds. John Wiley & Sons Ltd.

**Hubbard AR**, Dodt J, Lee T, Mertens, K, Seitz R, Srivastava A, Weinstein M (2013) Recommendations on the potency labeling of factor VIII and factor IX concentrates. J Thromb Haemost 11, 988-9